VEA
YMAB

Virtus ETF Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History

Virtus ETF Advisers’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,789
Closed -$280K – 809
2024
Q4 		$280K Buy
35,789
+8,457
+31% +$103K 0.11% 251
2024
Q3 		$359K Hold
27,332
– – 0.17% 212
2024
Q2 		$330K Buy
+27,332
New +$369K 0.16% 211
2022
Q2 		– Sell
-23,646
Closed -$281K – 479
2022
Q1 		$281K Hold
23,646
– – 0.13% 180
2021
Q4 		$383K Buy
23,646
+11,068
+88% +$237K 0.14% 169
2021
Q3 		$359K Sell
12,578
-1,150
-8% -$36.2K 0.16% 184
2021
Q2 		$464K Buy
13,728
+1,735
+14% +$55.7K 0.19% 173
2021
Q1 		$363K Buy
11,993
+331
+3% +$13.6K 0.15% 201
2020
Q4 		$577K Buy
11,662
+4,353
+60% +$201K 0.24% 125
2020
Q3 		$281K Sell
7,309
-1,000
-12% -$39.8K 0.15% 238
2020
Q2 		$359K Sell
8,309
-3,023
-27% -$114K 0.17% 255
2020
Q1 		$296K Sell
11,332
-1,671
-13% -$48.5K 0.12% 223
2019
Q4 		$406K Buy
+13,003
New +$385K 0.07% 249

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Virtus ETF Advisers's YMAB Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 35,789 shares — an estimated $280K sold.

Virtus ETF Advisers first reported a position in YMAB in Q4 2019 and held it in 13 quarters. The position peaked at $577K in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 35,789 Y-mAbs Therapeutics shares in Q1 2025, an estimated $280K.
  • Virtus ETF Advisers first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 13 quarters.
  • Virtus ETF Advisers's Y-mAbs Therapeutics position peaked at $577K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.